|
Secukinumab, trade name Cosentyx, is a human monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17.〔(【引用サイトリンク】publisher=American Medical Association )〕 It is highly specific to the human immunoglobulin G1k (IgG1k) subclass.〔 On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis. In July 2014 secukinumab established superiority to placebo and to etanercept for the treatment of chronic plaque psoriasis in Phase III clinical trials. In October 2014, the FDA Dermatologic and Ophthalmic Drugs Advisory Committee unanimously voted to recommend the drug for FDA approval, although this vote in and of itself does not constitute an approval. However, the FDA typically follows recommendations from these committees.〔http://www.familypracticenews.com/index.php?id=2934&type=98&tx_ttnews=306073〕 In October 2014, Novartis announced that the drug had achieved a primary clinical endpoint in two phase III clinical trials for ankylosing spondylitis.〔()〕 As of 28 October, the relevant FDA committee had not yet responded to these results. In early November 2014, Novartis also released the results of a Phase 3 study on psoriatic arthritis that yielded promising results.〔http://www.medpagetoday.com/MeetingCoverage/ACR/48743〕 Although the drug was originally intended to treat rheumatoid arthritis, phase II clinical trials for this condition yielded disappointing results.〔http://www.medscape.com/viewarticle/806510_6〕 Similarly, while patients in a phase II clinical trial for psoriatic arthritis did show improvement over placebo, the improvement did not meet adequate endpoints and Novartis is considering whether to do more research for this condition. Novartis has said that it is targeting approval and release in early 2015 for plaque psoriasis and ankylosing spondylitis indications. In January 2015 Novartis announced approval from the FDA to market secukinumab for moderate to severe plaque psoriasis. 〔http://www.novartis.com/newsroom/media-releases/en/2015/1888645.shtml〕 Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A). 〔http://www.psocialsis.com/medicamentos-det.php?recordID=42〕 A phase II clinical trial for multiple sclerosis completed in 2014 as it had exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Results of this trial have not yet been reported as of April 2015 == Standard protocol == Patients begin treatment with four booster shots of 300 mg subcutaneous each one taken a week apart, followed by regular injections once a month thereafter for 5 months. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Secukinumab」の詳細全文を読む スポンサード リンク
|